In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sesen Bio, Inc.

http://www.sesenbio.com/

Latest From Sesen Bio, Inc.

Keeping Track: Ticovac Is Latest Win For Pfizer’s Vaccine Business; Doors Open For BMS And GSK PD-1 Inhibitors

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Approvals Coronavirus COVID-19

Where Next For Sesen Bio’s Bladder Cancer Therapy Vicineum?

A complete response letter from the FDA has dashed Sesen Bio’s hopes of being first with a therapy for treating BCG-unresponsive non-muscle invasive bladder cancer. Its CEO says the FDA’s move may reflect heightened ‘pressure’ regulator is under.

Regulation Cancer

10 US Approval Decisions To Look Out For In Q3

This quarter has already seen a complete response letter for Iterum Therapeutics’ antibiotic sulopenem but a raft of other products are expecting approval decisions from the US Food and Drug Administration in the next three months. With the help of analysts at Biomedtracker, Scrip takes a look at 10 of the more interesting ones.

Approvals Companies

Oncology Accelerates In China As Large Makers Hunt For Assets

New regulatory measures shorten clinical trial approval times and usher in busy deal-making between large makers and smaller biotechs outside China.

China Cancer
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Eleven Biotherapeutics, Inc.
    • Viventia Bio Inc.
UsernamePublicRestriction

Register